Table 4 The potential biomarker in design of targeted nanomaterials in vascular anomalies
From: Recent advances in nanomaterial-driven strategies for diagnosis and therapy of vascular anomalies
Cellular and extracellular markers | |
|---|---|
Vascular tumors | |
Hemangioma Kaposiform hemangioendotheliomas Angiosarcoma | Glucose transporter 1 (Glut-1), Apelin receptor (APJ), CD31, CD34, CD133, FCg II receptor (FcgRII) [7, 8] PROX-1, D2-40, Claudin-5, VEGFR3, CD34, CD31, Fli-1, ERG, Claudin-5, D2-40 [11] CD31, CD34, Prox-1, Fli-1 [14] |
Vascular malformations | Â |
Capillary malformations Lymphatic malformations Venous malformations Arteriovenous malformations | CD133, CD166, EphB1, EfnB2 [159] D2-40, LYVE-1, VEGFR-3 [160] CD31 [148] – |